The effects of tamoxifen on homocysteine levels in breast cancer patients

• Authors: Aydan Eroğlu , Yonca Eğin , Nejat Akar
• Languages of publication: EN

Abstracts

EN

Tamoxifen is widely used in the treatment of breast cancer and associated with an increased risk of thromboembolism (TE). An elevated homocysteine is one of the risk factors for TE. The aim of the study was to assess the effect of tamoxifen on serum homocysteine levels in breast cancer patients. We performed a case-control study in 20 female subjects to evaluate the relationship between homocysteine levels, and 5,10-methylenetetrahyrofolate reductase (MTHFR) C677T and dihydrofolate reductase (DHFR) 19-bp intron-1 deletion polymorphisms in breast cancer patients and in control subjects. It was observed that homocysteine levels were decreased during tamoxifen therapy, but this finding was not statistically significant. There was also no statistically significant difference in homocysteine levels between the two groups (p> 0.05). MTHFR C677T and DHFR 19-bp deletion polymorphisms were not associated with serum homocysteine value in either group.

Keywords

EN

Breast cancer; Tamoxifen; Homocysteine; MTHFR; DHFR; Polymorphism

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 4
• Pages: 450-453

Dates

published

1 - 12 - 2009

online

3 - 10 - 2009

Contributors

author

Aydan Eroğlu

• Department of General Surgery, Ankara University Medical School, 06590, Ankara, Turkey

author

Yonca Eğin

• Department of Pediatric Molecular Genetic, Ankara University Medical School, 06590, Ankara, Turkey

author

Nejat Akar

• Department of Pediatric Molecular Genetic, Ankara University Medical School, 06590, Ankara, Turkey

References

• [1] Decousus H., Moulin N., Quenet S., Bost V., Rivron-Guillot K., Laporte S., et al., Thrombophilia and risk of venous thrombosis in patients with cancer, Thromb. Res., 2007, 120,Suppl 2, S51–S61 http://dx.doi.org/10.1016/S0049-3848(07)70130-5[Crossref]
• [2] Meier C.R., Jick H., Tamoxifen and risk of idiopathic venous thromboembolism, Br. J. Pharmacol., 1998, 45, 608–612 http://dx.doi.org/10.1046/j.1365-2125.1998.00733.x[Crossref]
• [3] Deitcher S.R., Gomes M.P., The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review, Cancer, 2004, 101, 439–449 http://dx.doi.org/10.1002/cncr.20347[Crossref]
• [4] Cushman M., Costantino J.P., Bovill E.G., Wickerham D.L., Buckley L., Roberts J.D., et al., Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial, Br. J. Haematol., 2003, 120, 109–116 http://dx.doi.org/10.1046/j.1365-2141.2003.03976.x[Crossref]
• [5] Duggan C., Marriott K., Edwards R., Cuzick J., Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer, J. Clin. Oncol., 2003, 21, 3588–3593 http://dx.doi.org/10.1200/JCO.2003.10.111[Crossref]
• [6] Çam R., Eroglu A., Egin Y., Akar N., Dihydrofolate reductase (DHFR) 19-bp intron-1 deletion and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms in breast cancer, Breast Cancer Res. Treat., 2008, DOI 10.1007/s10549-008-0054-x [Crossref][WoS]
• [7] Pemberton K.D., Melissari E., Kakkar V.V., The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis, Blood Coagul. Fibrinolysis, 1993, 4, 935–942 [Crossref]
• [8] Love R.R., Anker G., Yang Y., Refsum H., Ueland P.M., Lonning P.E., et al., Serum homocysteine levels in postmenopausal breast caner patients treated with tamoxifen, Cancer Letters, 1999, 145, 73–77 http://dx.doi.org/10.1016/S0304-3835(99)00233-5[Crossref]
• [9] Anker G., Lonning P.E., Ueland P.M., Refsum H., Lien E.A., Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen, Int. J. Cancer, 1995, 60, 365–368 http://dx.doi.org/10.1002/ijc.2910600316[Crossref]
• [10] Cattaneo M., Baglietto L., Zighetti M.L., Bettaga D., Robertson C., Costa A., et al., Tamoxifen reduces plasma homocysteine levels in healthy women, Br. J. Cancer, 1998, 77, 2264–2266
• [11] Eroglu A., Çam R., Yildiz Z., Akar N., PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer, Thromb. Res., 2003, 111, 317–319 http://dx.doi.org/10.1016/j.thromres.2003.09.011[Crossref]
• [12] den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B.J., Bos G.M.J., Hyperhomocysteinemia and venous thrombosis: a meta-analysis, Thromb. Haemost., 1998, 80, 874–877
• [13] Gellekink H., Blom H.J., van der Linden I.J.M., den Heijer M., Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels, Eur. J. Hum. Genet., 2007, 15, 103–109 http://dx.doi.org/10.1038/sj.ejhg.5201713[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-009-0020-y